Drug facts
MoleculeLenalidomide (Revlimid)
Generics already compete: 17 makers on the market. 107 A-rated products from 17 makers substitute at the counter.
Revlimid was first approved by the FDA on 12/27/2005 under NDA 021880; the application holder is Bristol Myers Squibb.
Holder Bristol Myers SquibbApplication NDA 021880Approved 12/27/2005
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
495days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved12/27/2005
Exclusivity ends05/28/2026
Last patent03/08/2028
2006201020142018202220262030
- Latest patent
- 03/08/2028Revlimid Orange Book
- Exclusivity
- 05/28/2026Revlimid Orange Book
02Competition
- Generics
- 17 generic makers Orange Book
- First generic approved
- 05/21/2021 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Lenalidomide profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Bristol Myers Squibb Orange Book
- Application
- NDA 021880 Orange Book
- First approved
- 12/27/2005 Orange Book
- Dosage forms
- capsule
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.